Discover Thomson Reuters
By Barbara Grzincic
1 Min Read
A split patent decision by a federal judge in Delaware will allow Swedish pharmaceutical firm Orexo AB and its U.S. subsidiary to hold off generic competition to its opioid-addiction drug Zubsolv for three more years, but not the 16 years the company sought.
U.S. District Judge Sue Robinson in Wilmington found a generic version of Zubsolv proposed by Teva Pharmaceutical subsidiary Actavis Elizabeth LLC infringed a 1998 patent asserted by Orexo.
To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2glpBVE
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
